Clinical Trial Update: Docetaxel Plus Bevacizumab in Metastatic Non Small Cell Lung Cancer [Phase 2]

View source ↗

Summary

A Phase 2 study of docetaxel plus bevacizumab for metastatic non-small cell lung cancer has been completed in a trial sponsored by the Hellenic Oncology Researc…

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Non-small Cell Lung Cancer

Drugs mentioned

• Bevacizumab (bevacizumab)
• DOCETAXEL (DOCETAXEL)

Snippet

Sponsor: Hellenic Oncology Research Group | Conditions: Non-small-cell Lung Cancer | Phase 2 | Status: COMPLETED